{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140"}]}],"title":"RP2D of dasatinib in the combination"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"RP2D of lenalidomide in the combination"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"RP2D dexamethasone in the combination"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"The RP2D was based on the MTD which was defined as the maximum combined dose producing dose limiting toxicity (DLT) in \\< 33% of participants treated at the individual dose levels in the combination. The MTD is considered the last dose level combination tested just below the maximum administered dose (MAD) level combination and for which DLTs were observed in less than or equal to 33% of participants during the escalation and expansion phase. If MTD was not reached Please refer to Outcome Measure 2 for the complete definition of DLT.","groups":[{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles; dasatinib (70/100 mg)QD for 28 days, dexamethasone (40mg)given weekly on Days 1, 8, 15, and 22 and lenalidomide (15/20/25mg)QD for 21 days.","id":"OG000","title":"All Treated Participants"}],"paramType":"NUMBER","populationDescription":"All treated participants, participants who received at least 1 dose of dasatinib.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to end of treatment (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).","title":"Recommended Phase II Dose (RP2D) of the Combination (Dasatinib + Lenalidomide + Dexamethasone)","type":"PRIMARY","unitOfMeasure":"mg"}